Results 1 to 10 of about 5,046 (110)

Radium-223 use and survival by line of treatment in metastatic castration-resistant prostate cancer: a nationwide population-based register study [PDF]

Acta Oncologica
Background: The role and optimal sequencing of radium-223 in the treatment of metastatic castration-resistant prostate cancer (mCRPC) remain debated.
Charlotte Alverbratt, Fredrik Sandin, Viktor Kolmbäck, Hans Garmo, Ola Bratt, Ingela Franck Lissbrant   +5 more
doaj   +2 more sources

Meaningful Radiographic and Metabolic Response to Enzalutamide Plus Radium‐223 Therapy in Metastatic Castration‐Resistant Prostate Cancer With PSA‐Discordant Progression: A Case Report [PDF]

IJU Case Reports
Introduction The combination of enzalutamide and radium‐223 has demonstrated clinical efficacy in metastatic castration‐resistant prostate cancer; however, real‐world evidence remains limited, particularly with PSA–discordant progression.
Yamato Numata, Go Kimura, Jun Akatsuka, Hikaru Mikami, Kotaro Obayashi, Yuki Endo, Hayato Takeda, Yuka Toyama, Ryuji Ohashi, Yukihiro Kondo   +9 more
doaj   +2 more sources

Drug Utilisation of Radium-223 Under Routine Clinical Practice (DIRECT) in Europe: A Post-Authorisation Safety Study [PDF]

Oncology and Therapy
Introduction Radium-223 is indicated for adults with metastatic castration-resistant prostate cancer (mCRPC) and symptomatic bone metastases, without visceral metastases, who progress after at least (≥) two lines of or are ineligible for other systemic ...
Rachel Weinrib, Joan Fortuny, David Martinez, Bianca Kollhorst, Ulrike Haug, Astrid Kousholt, Vera Ehrenstein, Peter Iversen, Jann Mortensen, Dianne Bosch, Malou Kuppen, Federica Pisa, Zdravko Vassilev   +12 more
doaj   +2 more sources

Clinical Outcome Patterns of Use of Radium-223 in Patients with Metastatic Castration-Resistant Prostate Cancer [PDF]

Current Oncology
Introduction: Radium-223 dichloride (radium-223) is a bone-targeting radioisotope therapy that aids in the survival of patients with metastatic castration-resistant prostate cancer (mCRPC) to bones.
Colleen Mackenzie, Jasna Deluce, Morgan Black, Emma Churchman, Eric Winquist, Scott Ernst, David T. Laidley, Matthew Parezanovic, Kylea Potvin, Ricardo Fernandes   +9 more
doaj   +2 more sources

GWAS from a multicenter prospective study of radium-223 in bone-metastatic castration-resistant prostate cancer [PDF]

EJNMMI Research
Background Radium-223 dichloride improves survival and delays symptomatic skeletal events in patients with bone-metastatic castration-resistant prostate cancer; however, therapeutic responses vary considerably among individuals, and predictive germline ...
Tokiyoshi Tanegashima, Masaki Shiota, Atsushi Doi, Shuichi Tatarano, Tomomi Kamba, Tsukasa Igawa, Naoya Masumori, Hirotsugu Uemura, Toshiyuki Kamoto, Katsuyoshi Higashijima, Kensuke Mitsunari, Hiroji Uemura, Takayuki Sumiyoshi, Takuro Isoda, Kousei Ishigami, Shoji Tokunaga, Masatoshi Eto   +16 more
doaj   +2 more sources

Bilateral neovascular glaucoma associated with Radium-223 infusions for prostate cancer [PDF]

American Journal of Ophthalmology Case Reports
Purpose: To report two cases of neovascular glaucoma associated with Radium-223 infusion. Observations: Presented are two patients with metastatic prostate cancer who developed uncontrolled intraocular pressure secondary to neovascular glaucoma requiring
Chelsea M. Viscardi, Jonathan Y. Rho, Charles R. Blake   +2 more
doaj   +2 more sources

The Tight Relationship Between the Tumoral Microenvironment and Radium-223 [PDF]

Biomedicines
Radium-223 (223Ra) was the first radioactive isotope approved for treating castration-resistant prostate cancer (CRPC) with symptomatic bone metastases without visceral metastatic disease.
Miriam Conte, Miriam Tomaciello, Maria Silvia De Feo, Viviana Frantellizzi, Francesco Marampon, Flaminia De Cristofaro, Giuseppe De Vincentis, Luca Filippi   +7 more
doaj   +2 more sources

Bone-Targeting Radionuclides in the Treatment of Metastatic Castration-Resistant Prostate Cancer: A Review on Radium-223 Chloride (Alpharadin) in Combination with Other Therapies [PDF]

Diagnostics
Recent advances have broadened the range of therapeutic options for mCRPC, with several new treatments, including novel hormonal therapies (enzalutamide, abiraterone), chemotherapeutic agents (docetaxel, cabazitaxel), immunotherapies (sipuleucel-T), and ...
Ali H. D. Alshehri
doaj   +2 more sources

Real-World Outcomes of Combination Therapy With Radium-223 and Enzalutamide Compared With Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer [PDF]

Advances in Urology
Radium-223 and enzalutamide have shown survival benefits in metastatic castration-resistant prostate cancer, and recent trial data suggest a potential synergy in combination.
Kenichi Hata, Yuma Goto, Masaki Hashimoto, Yusuke Takahashi, Yuki Takiguchi, Shun Saito, Yuya Iwamoto, Yuki Enei, Keigo Sakanaka, Akira Hisakane, Taisuke Yamazaki, Fumihiko Urabe, Takafumi Yanagisawa, Shunsuke Tsuzuki, Tatsuya Shimomura, Takahiro Kimura, Takanori Tojo, Hirohito Kobayashi   +17 more
doaj   +2 more sources

Predictive value of interim ¹¹C-choline PET/CT for response to radium-223 in metastatic castration-resistant prostate cancer [PDF]

EJNMMI Research
Background Radium-223 (Ra-223) has been approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC) with predominant osseous metastases.
Eman E. Ahmed, Jack R. Andrews, Mohamed E. Ahmed, Rimki Haloi, Lauren A. Rhodes, Mindie Mahon, Day A. Carter, Nancy Wei, Mattew P. Thorpe, Geoffrey B. Johnson, Eugene D. Kwon, Ayse Tuba Kendi   +11 more
doaj   +2 more sources